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Abstract
Objective: Systematic-reviews of analgesics for low back pain generally include published data only.
Obtaining data from unpublished trials is potentially important because they may impact effect
sizes in meta-analyses. We determined whether including unpublished data from trial registries
changes the effect sizes in meta-analyses of analgesics for low back pain.
Study Design and Setting: Trial registries were searched for unpublished data that conformed to the
inclusion criteria of n=5 individual source systematic-reviews. We reproduced the meta-analyses
using data available from the original reviews then re-ran the same analyses with the addition of
new unpublished data.
Results: Sixteen completed, unpublished, trials were eligible for inclusion in four of the source
reviews. Data were available for five trials. We updated the analyses for two of the source
reviews. The addition of data from two trials reduced the effect size of muscle relaxants,
compared to sham, for recent-onset low back pain from -21.71 (95%CI -28.23 to -15.19) to -2.34
(95%CI -3.34 to -1.34) on a 0-100 scale for pain intensity. The addition of data from three trials
(one enriched design) reduced the effect size of opioid analgesics, compared to sham, for chronic
low back pain from -10.10 (95%CI -12.81 to -7.39) to -9.31 (95%CI -11.51 to -7.11). The effect
reduced in the subgroup of enriched design studies, from -12.40 (95%CI -16.90 to -7.91) to 11.34 (95%CI -15.36 to -7.32), and in the subgroup of non-enriched design studies; from -7.27
(95%CI -9.97 to -4.57) to -7.19 (95%CI -9.24 to -5.14).
Conclusion: Systematic-reviews should include reports of unpublished trials. The result for muscle
relaxants conflicts with the conclusion of the published review and recent international
guidelines. Adding unpublished data strengthens the evidence that opioid analgesics have small
effects on persistent low back pain and more clearly suggests these effects may not be clinically
meaningful.
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What is New?
What is already known:


Systematic-reviews and meta-analyses that include unpublished data from trial registries may reach
different conclusions to those that exclude unpublished data.

What are the new findings:


Including unpublished data from trial registries changes the effect sizes reported in recently published
meta-analyses of common analgesic medicines for low back pain



Including unpublished data reduced the estimate of treatment effect in all comparisons for which
new data were available.



Current systematic-reviews of medicines for low back pain likely overestimate the benefits of these
interventions
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1. Introduction
Evidence from systematic-review and meta-analysis of data from controlled trials has an
important role in guideline development and clinical decision-making. It is well-known that not
all trials are published promptly, or indeed at all [1–3]. Unpublished data may substantially
impact effect sizes when included in published meta-analyses [4–9]. For example, including
unpublished data changed the effect size by up to 29% in 14 meta-analyses across cardiovascular
medicine, oncology, neurology and rheumatology [5]. Relatedly, published and unpublished data
may provide different estimates for the same comparison [10,11]. For example, the effect sizes
for comparisons amongst anti-depressant medicines may differ depending on whether the metaanalyses use data that are published, or data from regulatory submissions [10,11].

Analgesic medicines are a common treatment for the management of low back pain (LBP) [12–
16] and recent systematic-reviews of analgesic medicines [17–25], with a single exception [23],
only include published data. Clinical trial registries provide publicly accessible records of
unpublished trials and are recommended information sources for systematic-review teams
[26,27]. Despite this, a systematic literature search indicates the effect of including unpublished
data on the effect size of published meta-analyses of analgesic medicines for LBP remains
unknown.

The aim of this study was to evaluate the effect of including publicly available unpublished data,
identified through ClinicalTrials.gov and the World Health Organisation International Clinical
Trial Registry Platform (ICTRP), on the effect sizes of published meta-analyses of the most
commonly prescribed analgesic medicines for LBP.
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2. Methods
This review represents a supplementary analysis of five previously published systematic-reviews.

2.1 Published meta-analyses used in this study
We investigated systematic-reviews of paracetamol [19], non-steroidal anti-inflammatory drugs
(NSAIDs) [20,21], muscle relaxant medicines [18], and opioid analgesics [17] for people with
LBP. These were the five most recently published systematic-reviews at the time of writing the
protocol. Furthermore, these medicines are the most commonly prescribed for LBP
[12,13,15,16,28–30] and, with the exception of paracetamol, are recommended in recent
international guidelines for the management of LBP [31].

2.2 Search and selection process for unpublished data
Two authors independently extracted details of the inclusion criteria used in each of the previous
systematic-reviews (see eTable 1). Disagreements were resolved by discussion. Arbitration by a
third author was available if required. We developed a catalogue of analgesic medicines listed on
the World Health Organisation Anatomical Therapeutic Chemical classification system and
currently licensed in either Australia, Europe or the United States [32–34] (eTable 2). We adapted
the Saragiotto [19] and Enthoven [21] reviews’ search strategies for the ICTRP and
ClinicalTrials.gov, adding the medicines from the catalogue. For three reviews that did not search
trial registries [17,18,20], we developed separate search strategies de novo, using search terms for
LBP and the catalogued medicines. We used each strategy to search the ICTRP and
ClinicalTrials.gov for all trial records registered to the 6th of June 2017 – the most recent search
date from the included source systematic-reviews. A summary of the search strategies can be
found in eTable 3.
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We screened records against the previously extracted inclusion criteria for each review. Two
authors independently screened the title, keywords, and record description and subsequently
independently screened the full-record; defined as the full web-page, and any downloadable
documents. Disagreements were resolved by discussion. Arbitration by a third author was
available if required.

MKB verified the additional criteria for inclusion in this study that trials must have been i)
registered and ii) unpublished prior to the date of the last search by the respective source
systematic-review. Trials were judged unpublished when: i) the full record contained no listed
publications, ii) the downloaded dataset (where available) contained no listed publications and iii)
independent searches of PubMed [www.ncbi.nlm.nih.gov/pubmed], Google Scholar
[scholar.google.com.au/] and Google Search [www.google.com.au/webhp] using the record
registration number returned no results. The search and selection process is displayed in adapted
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagrams [35]
in eFigures 1-5. We also noted records of trials that were terminated or on-going, at the time of
the relevant review, in these diagrams.

2.3 Extraction and management of unpublished data
Two authors independently extracted all available data from full-records into a customised
spreadsheet using the same methods and data items as the previous reviews. This included
imputing missing standard deviations. The data availability status of eligible records is described
in the adapted PRISMA diagrams (eFigures 1-5). We did not contact the sponsors listed on trial
registry records to request additional data.
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2.4 Outcomes
The primary outcome in this study is the percentage change in effect size for the effect of an
analgesic medicine on a pain outcome in the previous review when available unpublished data
are included. We also reported the change in heterogeneity variance with the addition of new
unpublished data.

2.5 Data analysis
Two authors independently extracted data from each source systematic-review. We used these
data to reproduce the published meta-analyses for the effect of an analgesic medicine on a pain
outcome. We checked the forest plots against those in the original articles to verify accuracy. We
added all available new data from the trial registry records and calculated a pooled effect for the
unpublished data subgroup and a total pooled effect for the published and unpublished data
combined. We calculated the percentage change in effect size between the original meta-analysis
and the meta-analysis that combined published and unpublished data, following previously
described methods [5]. We tested the difference between the original and the combined metaanalyses using the Z-test implemented in Revman 5.3 [36,37]. We described heterogeneity in
each meta-analysis with the heterogeneity variance, Tau2.

2.6 Changes to the protocol and imputed data.
We used the full catalogue of analgesic medicines because the previous reviews [17–21] did not
report their inclusion criteria for interventions in greater detail than medicine class, e.g. muscle
relaxants. We also included hydrocodone, which was not on the World Health Organisation
Anatomical Therapeutic Chemical classification system, because it was included in the review of
opioid analgesics [17]. Searches for records of hydrocodone trials were conducted on the 14th of
June 2018. We searched ‘back pain’ in Condition instead of in Title [19,38] for the paracetamol
search strategy.
Journal of Clinical Epidemiology
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We imputed standard deviations for the following studies: EUCTR2012-001920-36,
NCT01358526 and NCT01455519. NCT00671502 reported between group differences and 95%
confidence intervals for the outcome score. We attempted to impute standard deviations by
calculating the standard error and then the standard deviation. However, the confidence intervals
were not symmetrical, suggesting the original data were skewed. We used the change score and
the standard deviation from NCT00671879 and adjusted the difference in change scores to
match the between group differences in outcome in NCT00671502. We tested the influence of
excluding NCT00671502 in sensitivity analyses. We determined post hoc to report the change in
the heterogeneity parameter and the change in sample size, in addition to the change in effect
size, for each of the meta-analyses.

The original meta-analysis of muscle relaxants [18] includes a single trial titled Berry 1988.
Whereas, two trials, Berry 1988a [39] and Berry 1988b [40], are reported in the ‘Characteristics of
included studies’ table. We obtained the paper for Berry 1988a [39] and followed the original
reviews’ [18] methods to add Berry 1988a [39] to the meta-analysis. We also evaluated the impact
of unpublished data on this meta-analysis.

2.7 Ethics and transparency
This study did not require ethical approval. It is a re-analysis of published systematic-reviews, using
data publicly available online. Our protocol is publicly accessible on the Open Science Framework
[38] and any discrepancies from the study as originally planned have been explained in the
preceding section. We have omitted the secondary outcome reported in the protocol for clarity
of presentation.
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3. Results
3.1 Paracetamol – Saragiotto et al.
We retrieved 66 records via the ICTRP and 76 via ClinicalTrials.gov. We screened 54 unique trial
records, excluded 52 and screened the full-record of the remaining two trials. We excluded both
records as one trial was published and the other was registered after the date of the last search
(eFigure 1).

3.2 NSAIDs – Enthoven et al.
We retrieved 103 records via the ICTRP and 94 via ClinicalTrials.gov. We screened 117 unique
trial records, excluded 82 and screened the full-record of the remaining 35 trials. Five records
were eligible for inclusion in the Enthoven review [21]. We did not include any of these trials as,
at the time of the Enthoven review [21], two trials had been terminated, a single trial was ongoing, a single trial had unknown status and the single completed trial did not have any data
available (eFigure 2).

3.3 NSAIDs – Machado et al.
The same 117 records were screened as for the Enthoven review. We excluded 64 records and
screened the full-record of the remaining 53 trials. Ten records were eligible for inclusion in the
Machado review [20]. We did not include any of these trials as, at the time of the Machado
review [20], four trials were on-going, a single trial had been terminated, a single trial had
unknown status and numeric outcome data were not available for the four completed trials
(eFigure 3).
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3.4 Muscle Relaxants – Abdel Shaheed et al.
3.4.1 Results of the search
We retrieved 45 records via the ICTRP and 43 via ClinicalTrials.gov. We screened 57 unique trial
records, excluded 31 and screened the full-record of the remaining 26 trials. Eight records were
eligible for inclusion in the Abdel Shaheed review [18]. We excluded 6 records as, at the time of
the Abdel Shaheed review [18], two trials were on-going, two trials had been terminated, a single
trial had unknown status and one of the three completed trials did not have data available. Data
were available for two of the three completed trials (NCT00671879 and NCT00671502) (eFigure
4). We included these two records in the updated meta-analysis.

3.4.2 Planned analysis
NCT00671879 (n=805) and NCT00671502 (n=840) contributed an additional 1645 participants,
an increase of 238.59%. We reproduced the meta-analysis of the effect (mean difference) of
muscle relaxant medicines on a 0-100 mm pain intensity scale, compared to a placebo medicine.
The inclusion of unpublished data from NCT00671879 and NCT00671502 reduced the pooled
effect size by 89.22%, from -21.71 (95%CI -28.23 to -15.19) to -2.34 (95%CI -3.34 to -1.34).
Tau2 reduced from 32.79 to 1.11 (Figure 1). The Chi2 test for a difference in effect size between
the published and unpublished subgroups was statistically significant (Chi2=39.36, p<.00001).
These data are summarised in Table 1.
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Figure 1. Effect of muscle relaxants on pain; short term; acute low back pain. Effect size is mean
difference, calculated using random effects inverse variance model in RevMan 5.3.
Outcome is 0-100 pain-intensity scale. 95% CIs for the unpublished data subgroup are not
visible at this resolution. Placebo group Total was split to incorporate multi-arm trials as per
[18]. Medicines in published data subgroup are as per [18]. NCT00671502_a and
NCT00671879_a are carisoprodol 500mg SR, _b are carisoprodol 700mg SR.
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Table 1. Number of additional, unpublished trials retrieved from trial registries and change in effect size when available data are added to the published metaanalysis. Methods for searching, selection and analysis of unpublished trials from trial registries followed exactly those used in the original reviews.
Number of trials (Number of subjects randomised)
Medicine

Included
in
original
SR (all)

Unpublished
trials eligible
for inclusion
in original SR

Unpublished,
completed

Unpublished,
completed,
data available

Paracetamol
[19]
NSAIDs [21]

0

NA

5

Muscle
Relaxants [18]

3
(n=1825)
13
(n=4807)
35
(n=6065)
15
(n=3362)

1
(n=127)
4
(n=1699)
3
(n=1841)

2
(n=1680)

Opioids [17]
Combination

20
(n=6869)

11

8
(n=3251)

3
(n=1273)

Opioids [17]
Enriched

9
(n=2996)

6

6
(n=2579)

1
(n=601)

Opioids [17]
Nonenriched

11
(n=3873)

5

2
(n=672)

2
(n=672)

NSAIDs [20]

10
8

Effect Size
Outcome
(scale)

Original SR
(95%CI)

Original SR
[reproduced]
(95%CI)

Unpublished
data added

Weight
of new
trials
(%)

Change
in effect
size (%)

Direction
of change
in effect
size

Change in
statistical
significance

Change in
clinical
meaningfulness

Test for
difference
between
subgroups

NA

NA

NA

NA

NA

0

0

nil

nil

nil

NA

0

NA

NA

NA

NA

0

0

nil

nil

nil

NA

0

NA

NA

NA

NA

0

0

nil

nil

nil

NA

Pain
intensity,
short term
(0-100)
Pain
intensity,
short term
(0-100)
Pain
intensity,
short term
(0-100)
Pain
intensity,
short term
(0-100)

-21.3
(-29 to -13.5)

-21.71
(-28.23 to 15.19)

-2.34 (-3.34
to -1.34)

92.9

89.22

Decrease
efficacy

nil

Yes

Chi2=39.36
p<.00001

-10.10
(-12.8 to 7.4)

-10.10
(-12.81 to 7.39)

-9.31
( -11.51 to 7.11)

21.1

7.82

Decrease
efficacy

nil

nil

Chi2=4.98
p=.03

-12.40
(-16.9 to
-7.9)

-12.40
(-16.90 to
-7.91)

-11.34 (15.36 to 7.32)

13

8.55

Decrease
efficacy

nil

nil

Chi2=7.67
p=.006

-7.3
(-10 to -4.6)

-7.27
(-9.97 to
-4.57)

-7.19 (-9.24
to -5.14)

18.8

1.1

Decrease
efficacy

nil

nil

Chi2=0.15
p=.70

3.4.3 Sensitivity analysis – inclusion of NCT00671879 only
The inclusion of unpublished data from NCT00671879 only, reduced the pooled effect size by
69.09% to -6.71 (95%CI -8.86 to -4.56). Tau2 reduced from 32.79 to 3.29.

3.4.4 Additional analyses
3.4.4.1 Inclusion of Berry 1988a in original meta-analysis
The inclusion of Berry 1988a reduced the pooled effect size of the original meta-analysis from 21.71 (95%CI -28.23 to -15.19) to -17.98 (95%CI -26.72 to -9.25). Tau2 increased from 32.79 to
102.53.

3.4.4.2 Inclusion of unpublished data to meta-analysis containing Berry 1988a
The inclusion of unpublished data from NCT00671879 and NCT00671502 reduced the pooled
effect size by 87.15% to -2.31 (95%CI -3.30 to -1.31). Tau2 reduced from 102.53 to 1.10.

3.4.4.3 Sensitivity analysis – inclusion of NCT00671879 only to meta-analysis containing Berry 1988a
The addition of unpublished data from NCT00671879 only, reduced the effect size by 64.46% to
-6.39 (95%CI -8.48 to -4.29). Tau2 reduced from 102.53 to 3.27.

3.5 Opioid analgesics – Abdel Shaheed et al.
3.5.1 Results of the search
We retrieved 114 records via the ICTRP and 153 via ClinicalTrials.gov. We screened 138 unique
trial records, excluded 43 records and screened the full-record of the remaining 95 trials. Eleven
trials were eligible for inclusion in the Abdel Shaheed review [17]. We excluded eight records as,
at the time of the Abdel Shaheed review [17], a single trial was on-going, a single trial had been
terminated, a single trial had unknown status and data were not available for five of the eight
completed trials. Data were available for three of the eight completed trials (EUCTR2012Journal of Clinical Epidemiology
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001920-36, NCT01358526, NCT01455519) (eFigure 5). We included these three records in the
updated meta-analyses.

3.5.2 Planned analysis
The original review [17] conducted meta-analyses of the short- and intermediate-term effects of
single-ingredient opioid analgesics and of the intermediate-term effect of opioid/simple analgesic
combinations on a 0-100 mm pain intensity scale, compared to a placebo medicine. These
analyses considered enriched-enrolment (participants are selected based on response to openlabel intervention, following which they are randomised to continue or withdraw from the
intervention [41]) and non-enriched (conventional) designs as separate subgroups as well as a
combined analysis of both enriched and non-enriched designs. We did not retrieve any new data
for effects in the intermediate term, nor for combination formulations. Thus, we only
reproduced the meta-analyses of the short-term effect of single-ingredient opioid analgesic
medicines.

NCT01358526 contributed an additional 600 participants to the enriched designs analysis, an
increase of 135.52%. The inclusion of unpublished data from NCT01358526 reduced the pooled
effect size of the enriched designs meta-analysis by 8.55% from -12.40 (95%CI -16.90 to -7.91)
to -11.34 (95%CI -15.36 to -7.32). Tau2 reduced from 33.51 to 29.71 (Figure 2). The difference in
effect size between the published and unpublished trials was statistically significant (Chi2=7.67,
p=.006) (Table 1).
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Figure 2. Single ingredient opioid analgesic vs placebo. Short term. Enriched design. Effect size
is mean difference, calculated using random effects inverse variance model in RevMan 5.3.
Outcome is 0-100 pain-intensity scale. Placebo group Total was split to incorporate multiarm trials as per [17]. Medicines in published data subgroup are as per [17]. NCT01358526
is oxycodone/naloxone.

EUCTR2012-001920-36 (n=607) and NCT01455519 (n=26) contributed an additional 633
participants to the non-enriched designs analysis, an increase of 136.59%. The inclusion of
unpublished data from EUCTR2012-001920-36 and NCT01455519 reduced the pooled effect
size of the non-enriched designs meta-analysis by 1.1% from -7.27 (95%CI -9.97 to -4.57) to 7.19 (95%CI -9.24 to -5.14). Tau2 reduced from 3.63 to zero (Figure 3). There was no difference
identified in effect size between the published and unpublished trials (Chi2=0.15, p=.70) (Table
1).
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Figure 3. Single ingredient opioid analgesic vs placebo. Short term. Nonenriched design. Effect
size is mean difference, calculated using random effects inverse variance model in RevMan
5.3. Outcome is 0-100 pain-intensity scale. Placebo group Total was split to incorporate
multi-arm trials as per [17]. Medicines in published data subgroup are as per [17].
EUCTR2012-001920-36_a is cebranopadol 200mg, _b is cebranopadol 400mg, _c is
cebranopadol 600mg, _d is tapentadol and NCT01455519 is hydromorphone ER.

NCT01358526 (n=600), EUCTR2012-001920-36 (n=607) and NCT01455519 (n=26)
contributed an additional 1233 participants to the combined designs analysis, an increase of
136.1%. For the combined analysis of both enriched and non–enriched designs the inclusion of
unpublished data from EUCTR2012-001920-36, NCT01358526, and NCT01455519 reduced the
pooled effect size by 7.82% from -10.10 (95%CI -12.81 to -7.39) to -9.31 (95%CI -11.51 to 7.11). Tau2 reduced from 19.73 to 14.46 (Figure 4). The difference in effect size between the
published and unpublished trials was statistically significant (Chi2=4.98, p=.03) (Table 1).
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Figure 4. Single ingredient opioid analgesic vs placebo. Short term. Enriched and nonenriched
designs. Effect size is mean difference, calculated using random effects inverse variance
model in RevMan 5.3. Outcome is 0-100 pain-intensity scale. Placebo group Total was
split to incorporate multi-arm trials as per [17]. Medicines in published data subgroup are
as per [17]. NCT01358526 is oxycodone/naloxone, EUCTR2012-001920-36_a is
cebranopadol 200mg, _b is cebranopadol 400mg, _c is cebranopadol 600mg, _d is
tapentadol and NCT01455519 is hydromorphone ER.

4. Discussion
We aimed to determine the effect of including publicly available, unpublished data from trial
registries on the effect sizes of published meta-analyses of the most commonly used analgesic
medicines for LBP. We clearly show that such data reduced the effect sizes of muscle relaxant
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and opioid-analgesic medicines for LBP. These results have implications for future evidence
synthesis and for the interpretation of evidence in this field.

The biggest impact of including unpublished trial registry data was observed for muscle relaxant
medicines - an 87% decrease in effect size. The minimal clinically important difference between
groups for back pain intensity is considered to be 10 points on a 0-100 point scale [24,42]. The
original review reported an effect size greater than this [-21.71 (95%CI -28.23 to -15.19)] [18].
However, the addition of unpublished data yielded a revised effect size that, although statistically
significant, was well short of the clinically meaningful threshold [-2.34 (95%CI -3.34 to -1.34)]
and with much less heterogeneity. Clearly, adding unpublished data changes the precision and
clinical meaning of the effect size. The Abdel Shaheed study [18] is the largest and most recent
review of these medicines for LBP. Updates of this review or future syntheses of evidence for
these medicines should include unpublished data.

These implications extend to future clinical guidelines. Clinical guidelines have an important role
in directing the use of appropriate interventions in practice. The recommendations are often
informed by systematic-reviews. The current American College of Physicians/American Pain
Society clinical guideline for the management of LBP makes a strong recommendation for the
use of muscle relaxant medicines for recent-onset LBP [43]. This recommendation is based on
data from a systematic-review, published in 2003 [44], and additional update searches [24].
Although data were analysed differently, the 2003 review reported an effect of a similar
magnitude as that reported in the recent review sampled in our study. We note that the updated
search included unpublished data sources, although none were identified for muscle relaxants.
Clearly, guideline developers should search for and include unpublished data if conducting
systematic-reviews or be more cautious of their interpretation of pooled estimates taken from
systematic-reviews that do not include unpublished data.
Journal of Clinical Epidemiology
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We have also shown that the effect estimates for opioid analgesic medicines reduced with the
inclusion of unpublished data. The authors of the original review concluded that opioid
analgesics probably do not provide clinically meaningful effects at recommended doses based on
the results of the combined designs analysis [-10.10 (95%CI -12.81 to -7.39)] [17]. The reduced
size and heterogeneity and improved precision of the effect estimate [-9.31 (95%CI -11.51 to 7.11)] with the inclusion of unpublished data substantiate the conclusion of the original review.

Our results also have implications for the judgements of confidence in evidence that are made by
systematic review teams. These judgements interpret the meta-analytic effect estimates in the
context of possible bias, observed heterogeneity and missing data. A well-known framework for
making these judgements is GRADE [45]. The original analyses of muscle relaxants and opioid
analgesics were both judged using the GRADE framework; whereby the review teams judged the
evidence to be high quality for the effect of muscle relaxant medicines [18] and moderate quality
for the effect of opioid analgesic medicines [17] on short term pain intensity, compared to a
placebo medicine. In both cases, the additional unpublished trials have implications for the
judgement of confidence in the effect estimates from the updated analyses. However,
examination of these implications is beyond the scope of this study.

Our work has a number of strengths. We prospectively registered and followed a protocol [38],
now recommended practice in the clinical pain sciences [46]. We have reported all protocol
deviations and post hoc decisions, to facilitate clear understanding of our work. We used sensitive
search strategies for a large number of currently licensed analgesic medicines. We reproduced the
methods of the previous reviews as precisely as possible, which increases the likelihood that our
results are due to the influence of the unpublished data and not to the reproduction process.
Additionally, we extracted data in duplicate and cross-checked all of our analyses.
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Our work has some limitations. We restricted the scope of unpublished data sources to trial
registrations. There are multiple sources of data from controlled clinical trials; websites,
regulatory agencies, direct contact with trialists, and data sharing networks [26,47,48]. The
sample we have drawn may not be representative of all unpublished data. Our work relied on
accurate reporting of the identified trials’ data on the registries. The availability and veracity of
trial registry data are known considerations [49–54]. We note that the reported standard
deviations for NCT00671879 are smaller than other trials in the analyses of muscle relaxant
medicines (Figure 1). We may have been able to obtain data or clarification had we contacted the
sponsors of the relevant trials. However, access to data and clarification is not universal, may
incur restrictions and often require significant effort to obtain, with no guarantee of success
[47,48,55,56]. These are relevant considerations for review production teams. Further, we aimed
only to determine the influence of unpublished data, rather than update the previous reviews.
For these reasons, we are confident that the restriction of our sampling to trial registries is
justified. We welcome further work to evaluate the influence of other sources of unpublished
data.

We developed a catalogue of medicines for this study. We note that eperisone is a muscle
relaxant medicine included in the Abdel Shaheed review [18] but not in our catalogue. We
searched post hoc for trials of eperisone for back pain and identified 14 trials. Three of these trials
do not meet the inclusion criteria for this study and 11 do not have data available. Thus, the
exclusion of eperisone does not impact our conclusions.

We established publication status using a three-step rule. There is the potential that we
misclassified studies as unpublished that have in fact been published. This is most likely because
the published report does not include the trial registry identification number. We note that
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alternative methods for identifying publication status have been reported [8,50,56–60]. These
exhibit some overlap with our methods, primarily the use of the trial identification number.
Regardless of the methods used, accurate reporting is important to facilitate understanding of
these judgements. This standard of reporting is in line with recommendations [35,61–63].

We note that five systematic-reviews of analgesic medicines for LBP have been published [22–
25,64] subsequent to the registration of our protocol. Four of these reviews [22–25] searched
trial registries for reports of unpublished trials (although, no trials were available for metaanalysis). This indicates that research practice in the field may be changing. The results of our
study provide the first evidence to support this change in practice.

5. Conclusion
Most systematic-reviews of analgesic medicines for LBP do not include unpublished data from
clinical trial registries. Including unpublished data in recent meta-analyses reduced the estimate of
treatment effect in all comparisons for which new data were available. This suggests that current
systematic-reviews of medicines for LBP likely overestimate the benefits of these drugs.
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